Zimmer Biomet price target lowered to $140 from $160 at JMP Securities

JMP Securities lowered the firm’s price target on Zimmer Biomet to $140 from $160 and keeps an Outperform rating on the shares following the Q3 earnings report. JMP believes Zimmer is well positioned to make meaningful steps toward the long-term strategy of its core franchises achieving “at or above market growth rates,” and management previously noted that it feels more comfortable with an 4% growth range ahead in a normal environment, the analyst tells investors in a research note.